Clinical Trials Logo

Advanced Solid Tumor Malignancy clinical trials

View clinical trials related to Advanced Solid Tumor Malignancy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05501821 Recruiting - Clinical trials for Advanced Solid Tumor Malignancy

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Start date: August 8, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors

NCT ID: NCT04260529 Active, not recruiting - Clinical trials for Advanced Solid Tumor Malignancy

CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations

CICILIA
Start date: April 30, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy and in combination with anti-PD-1 antibody pembrolizumab. Additionally, the trial will monitor anti-tumor effects on both injected lesions and distant non-injected deposits.

NCT ID: NCT02380677 Terminated - Clinical trials for Advanced Solid Tumor Malignancy

Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2a, open-label, dose-escalation study with enrollment in Phase 1 to continue until determination of the Maximum Tolerated Dose (MTD) /Recommended Phase 2a Dose (RP2D), and then enrollment into Phase 2a expansion cohorts will be initiated.